# [http://www.euromonitor.com Euromonmitor International]
# [http://www.bccresearch.com BCC Research]
# [http://www.ibisworld.com/ IBISWorld Industry Research]
# [http://www.marketresearch.com MarketResearch.com]
# [http://www.frost.com/prod/servlet/frost-home.pag Frost and Sullivan]
[[Image:Global AcneBCC ACNE.jpg|center|thumb|center|632px * 341px|Source:BCC Research,[http://www.marketresearch.com/BCC-Research-v374/Skin-Disease-Treatment-Technologies-Global-7616658]]] {|border="0" cellspacing="0" cellpadding = "0" width="100%"|align = "center"|<font color="#282828"><font size = "4">'''The Acne Product Pipeline'''</font></font>|-|} {|border="2" cellspacing="0" cellpadding="4" width="100%" align="center"|align = "center"|<br>''' ''' '''Product'''|align = "center"|''' '''<br>'''Company'''|align = "center"|<br>''' Indication'''|align = "center"|<br>'''Development Status'''|-|ACAT Inhibitor|Graceway Pharmaceuticals|Acne|Phase II|-|ANT-1207 (botulinum toxin A)|Anterios|Acne vulgaris|Phase II|-|ASC-J9|AndroScience|Acne vulgaris|Phase II|-|AUS-131/doxycycline|Nexgen Dermatologics|Acne vulgaris|Phase I/II|-|BLI-1100|Braintree Laboratories|Acne vulgaris|Phase II|-|CD-07223|Galderma R &D|Acne|Phase II|-|CD-2475-101|Galderma Laboratories|Acne vulgaris|Phase I|-|Clindamycin/tretinoin topical combination|Skinvisible Pharmaceuticals|Acne|In clinical trials|-|COL-177|Onset Dermatologics|Acne vulgaris|In clinical trials|-|Duac Topical Gel low-dose clindamycin/benzoyl peroxide gel|Stiefel, a GSK company|Acne vulgaris|Application submitted|-|E-0301|Elorac|Acne|Phase III|-|IDP 107|Valeant Pharmaceuticals|Acne vulgaris|Phase II|-|Isotretinoin|Cipher Pharmaceuticals|Acne|Phase III|-|JNJ-10229570|Johnson & Johnson|Acne vulgaris|Phase II|-|Metvixia|PhotoCure methyl aminolevulinate|Acne|Phase II|-|NB-003 (nanoemulsion)|NanoBio|Acne|Phase I|-|NVC-422|Galderma|Acne|Phase I completed|-|Tazarotene foam (retinoid foam)|Stiefel, a GSK company|Acne vulgaris|Phase III|-|Tretinoin topical|Phosphagenics|Acne|Phase I|-|WC-3018|Warner Chilcott|Acne|Phase II|-|WC-3035|Warner Chilcott|Acne|Phase I|-|}<br clear="all"> {|border="0" cellspacing="0" cellpadding = "0" width="100%"|<font color="#282828"> Source: [http://www.phrma.org/sites/default/files/pdf/skindiseases2011.pdf Pharmaceutical Research and Manufacturers of America, 2011]
== '''USA market study''' ==
===Historic Sales===
* The Acne Treatment Manufacturing OTC industry has maintained strong growth during the past five years. From As per IBIS World estimates from 2007 to 2012, revenue has grown unabatedsteady, and it is expected to expand grow at an average annual rate of 2.4% to $2.3 billion.
* Because acne-prone individuals consider treatment products a necessary expense, revenue continued to rise during the recession, though growth did slow as consumers switched to more inexpensive products.
* Increasing prevalence of adult-onset and persistent acne conditions has given rise to new, targeted products and an expanded consumer base, another factor that has aided revenue growth during the period.
* . In 2012, industry revenue is expected to maintain its growth, gaining 2.7% during the year, due to modest improvements in per capita disposable income.
[[Image:USACNE2012.jpg|center|thumb|center|632px * 341px|Source:IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html]]]
===Industry Forecast===
[[Image:Anti Acne Treatment market* From 2012 to 2017, industry revenue is expected to go up an annualized rate of 3.jpg|700px|thumb|center|[http://academic1% to $2.marketresearch7 billion from current level of $2.com/product/display3 billion.asp?productid=1658180&curl=&surl=%2Fsearch%2Fresults* Improving economic conditions is likely to drive the market, as greater disposable income growth allows consumers to spend on higher-priced over-the-counter (OTC) items.asp%3Fprid%3D925717062%26query%3Dthe%2BU.S.%2Bcosmeceuticals%2Bmarket%26cmdgo%3DGo&prid=925717062 Source]]]
===Major Players in Acne Space===
J&J commanded over 47% of anti-[[Image:US2018 acne preparation sales in 2007. About 27 points of that share was yielded by the Neutrogena brand and another 16 points by Clean & Clear. J&J’s closest rival was Reckitt Benckiserjpg|center|thumb|center|632px * 341px|Source:IBIS World, which had only a 15% share, thanks to its early 2006 acquisition of Boots Healthcare and its time[http://www.ibisworld.com/industry/acne-treatment-manufacturing-honored Clearasil brandotc. html]]]
Share of U.S. Retail Dollar Sales of Anti-Acne Preparations ===Major Players in Mass Channels for 2007 are shown belowAcne Space===Mass Channel * As per IBIS World estimates the top three industry players (Mass channel includes mainstream supermarketsJohnson & Johnson, chain drugstores Guthy-Renker and mass merchandisersReckitt-Benckiser)hold a combined market share of about 68. Various Channels 1%, in 2012. The rest of Distribution:the market is characterized by a large number of small and medium-size businesses.
* Mass channel includes mainstream supermarketsJ&J (Neutrogena, chain drugstores and mass merchandisersClean & Clear, Aveeno, Ambi) commanded over 28. * Prestige includes upscale8% of anti-priced department stores (e.gacne preparation sales in 2012.J&J’s closest rival was Guthy Renker, Bloomingdale's, Nordstrom), beauty chains (SephoraProactiv Solutions), brand-dedicated stores (Aveda, Mwhich had a 24.A6% share followed by Reckitt Benckiser at 14.C.), salons and spas with retail counters, etc7%.* Online Stores* Direct Sales
[[Image:Major PlayersUS Acne Share.jpg |700pxUS Acne Share.jpg|thumb|center|632px * 341px|Source:IBIS World,[http://academicwww.marketresearchibisworld.com/productindustry/displayacne-treatment-manufacturing-otc.asp?productid=1658180&curl=&surl=%2Fsearch%2Fresults.asp%3Fprid%3D925717062%26query%3Dthe%2BU.S.%2Bcosmeceuticals%2Bmarket%26cmdgo%3DGo&prid=925717062 Sourcehtml]]]
===Consumer Target Group & Product Categorization===
